Zhejiang Shanyuan Pharmaceutical

Shanyuan Pharmaceutical is a clinical-stage biopharmaceutical company based in Zhejiang, China, focused on the discovery and development of innovative small molecule therapeutics for metabolic diseases and oncology. The company specializes in targeting high-value pathways such as GLP-1 and THR-beta to address unmet medical needs in conditions like Type 2 diabetes, obesity, and nonalcoholic steatohepatitis (NASH). Shanyuan leverages its internal R&D capabilities to advance a pipeline of candidates through clinical trials, aiming to provide more effective and safer treatment options for patients globally. The firm is led by a team of industry veterans with extensive experience in global drug development and commercialization.